JP2008513513A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008513513A5 JP2008513513A5 JP2007532679A JP2007532679A JP2008513513A5 JP 2008513513 A5 JP2008513513 A5 JP 2008513513A5 JP 2007532679 A JP2007532679 A JP 2007532679A JP 2007532679 A JP2007532679 A JP 2007532679A JP 2008513513 A5 JP2008513513 A5 JP 2008513513A5
- Authority
- JP
- Japan
- Prior art keywords
- decoy
- seq
- microemulsion
- tissue
- inflammation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000004530 micro-emulsion Substances 0.000 claims 12
- 239000000203 mixture Substances 0.000 claims 9
- 206010061218 Inflammation Diseases 0.000 claims 6
- 230000004054 inflammatory process Effects 0.000 claims 6
- 108010057466 NF-kappa B Proteins 0.000 claims 5
- 102000003945 NF-kappa B Human genes 0.000 claims 5
- 108091034117 Oligonucleotide Proteins 0.000 claims 5
- 239000002773 nucleotide Substances 0.000 claims 3
- 125000003729 nucleotide group Chemical group 0.000 claims 3
- 108020004414 DNA Proteins 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000000770 proinflammatory effect Effects 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 claims 1
- 102000053602 DNA Human genes 0.000 claims 1
- 102000004889 Interleukin-6 Human genes 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- BACYUWVYYTXETD-UHFFFAOYSA-N N-Lauroylsarcosine Chemical compound CCCCCCCCCCCC(=O)N(C)CC(O)=O BACYUWVYYTXETD-UHFFFAOYSA-N 0.000 claims 1
- PKFBJSDMCRJYDC-GEZSXCAASA-N N-acetyl-s-geranylgeranyl-l-cysteine Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CSC[C@@H](C(O)=O)NC(C)=O PKFBJSDMCRJYDC-GEZSXCAASA-N 0.000 claims 1
- 102000005395 NF-kappa B p50 Subunit Human genes 0.000 claims 1
- 108010006401 NF-kappa B p50 Subunit Proteins 0.000 claims 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 claims 1
- 102000005747 Transcription Factor RelA Human genes 0.000 claims 1
- 108010031154 Transcription Factor RelA Proteins 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000002337 electrophoretic mobility shift assay Methods 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000000833 heterodimer Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 239000003961 penetration enhancing agent Substances 0.000 claims 1
- 108700004121 sarkosyl Proteins 0.000 claims 1
- 229940057950 sodium laureth sulfate Drugs 0.000 claims 1
- SXHLENDCVBIJFO-UHFFFAOYSA-M sodium;2-[2-(2-dodecoxyethoxy)ethoxy]ethyl sulfate Chemical compound [Na+].CCCCCCCCCCCCOCCOCCOCCOS([O-])(=O)=O SXHLENDCVBIJFO-UHFFFAOYSA-M 0.000 claims 1
- 229940035044 sorbitan monolaurate Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61204604P | 2004-09-21 | 2004-09-21 | |
| US66349705P | 2005-03-18 | 2005-03-18 | |
| PCT/US2005/034110 WO2006034433A2 (en) | 2004-09-21 | 2005-09-21 | Delivery of polynucleotides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008513513A JP2008513513A (ja) | 2008-05-01 |
| JP2008513513A5 true JP2008513513A5 (enExample) | 2009-03-05 |
Family
ID=36090693
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007532679A Pending JP2008513513A (ja) | 2004-09-21 | 2005-09-21 | ポリヌクレオチドの送達 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20060069055A1 (enExample) |
| EP (1) | EP1799271A4 (enExample) |
| JP (1) | JP2008513513A (enExample) |
| AU (1) | AU2005286640A1 (enExample) |
| CA (1) | CA2583413A1 (enExample) |
| MX (1) | MX2007003167A (enExample) |
| WO (1) | WO2006034433A2 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005056795A2 (en) * | 2003-12-03 | 2005-06-23 | Corgentech, Inc. | Hif oligonucleotide decoy molecules |
| KR20070044805A (ko) * | 2004-04-15 | 2007-04-30 | 키아스마, 인코포레이티드 | 생물학적 장벽 투과를 촉진시킬 수 있는 조성물 |
| US20070219131A1 (en) * | 2004-04-15 | 2007-09-20 | Ben-Sasson Shmuel A | Compositions capable of facilitating penetration across a biological barrier |
| US9486408B2 (en) | 2005-12-01 | 2016-11-08 | University Of Massachusetts Lowell | Botulinum nanoemulsions |
| US8530436B2 (en) * | 2007-01-29 | 2013-09-10 | Transderm, Inc. | Methods and compositions for transdermal delivery of nucleotides |
| CA2680801A1 (en) * | 2007-03-14 | 2008-09-18 | Sierra Molecular Corporation | Compositions, systems, and methods for preservation and/or stabilizationof a cell and/or macromolecule |
| DK2158316T3 (en) | 2007-05-11 | 2015-07-20 | Adynxx Inc | Gene expression and pain |
| JP5294302B2 (ja) * | 2008-03-28 | 2013-09-18 | マルホ株式会社 | 胸腺間質リンパ球増殖因子産生を評価するスクリーニング方法 |
| ES2629131T3 (es) | 2008-09-17 | 2017-08-07 | Chiasma Inc. | Composiciones farmacéuticas y métodos de suministro relacionados. |
| SG10201804552WA (en) * | 2011-01-24 | 2018-07-30 | Anterios Inc | Nanoparticle compositions, formulations thereof, and uses therefor |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| AU2013243952A1 (en) | 2012-04-02 | 2014-10-30 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US10501513B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides for the production of oncology-related proteins and peptides |
| HK1206612A1 (en) * | 2012-04-02 | 2016-01-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of secreted proteins |
| US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
| RU2668136C2 (ru) | 2012-05-10 | 2018-09-26 | Эйдинкс, Инк. | Композиции для доставки активных ингредиентов |
| CN106661578B (zh) | 2014-08-15 | 2020-08-04 | 埃迪恩克斯股份有限公司 | 用于疼痛治疗的寡核苷酸诱饵 |
| RS66942B1 (sr) | 2015-02-03 | 2025-07-31 | Amryt Endo Inc | Lečenje akromegalije oralnim oktreotidom |
| KR102487144B1 (ko) | 2016-11-21 | 2023-01-12 | 에이리온 테라퓨틱스, 인코포레이티드 | 큰 물질의 경피 전달 |
| CA3057243A1 (en) * | 2017-03-23 | 2018-09-27 | Lipid Systems Sp. Z.O.O. | High-efficiency encapsulation of hydrophilic compounds in unilamellar liposomes |
| US12233073B2 (en) * | 2017-06-09 | 2025-02-25 | Regents Of The University Of Minnesota | Skin care formulations and skin cancer treatment |
| US11141457B1 (en) | 2020-12-28 | 2021-10-12 | Amryt Endo, Inc. | Oral octreotide therapy and contraceptive methods |
| CN114469897B (zh) * | 2022-01-12 | 2023-02-28 | 上海市胸科医院 | 靶向治疗心肌梗死的锂皂石复合递送材料及其制备与应用 |
| US20230406888A1 (en) * | 2022-04-27 | 2023-12-21 | Sachi Bioworks Inc. | Methods and systems for targeting autoimmune and inflammatory pathways using nanoligomers |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6150090A (en) * | 1986-01-09 | 2000-11-21 | Massachusetts Institute Of Technology | Nuclear factors associated with transcriptional regulation |
| US6262022B1 (en) * | 1992-06-25 | 2001-07-17 | Novartis Ag | Pharmaceutical compositions containing cyclosporin as the active agent |
| US6699985B2 (en) * | 1991-08-21 | 2004-03-02 | Arsinur Burcoglu | Method of treating HIV infection and related secondary infections thereof |
| US6399376B1 (en) * | 1993-11-05 | 2002-06-04 | Isis Pharmaceuticals, Inc. | Modulation of vascular cell adhesive molecule expression through oligonucleotide interactions |
| ATE357922T1 (de) * | 1995-05-12 | 2007-04-15 | Anges Mg Inc | Heilung und vorbeugung von durch nf-kappab verursachten erkrankungen |
| JP2002510319A (ja) * | 1997-07-01 | 2002-04-02 | アイシス・ファーマシューティカルス・インコーポレーテッド | オリゴヌクレオチドの消化管を介したデリバリーのための組成物及び方法 |
| US6890909B1 (en) * | 1997-07-04 | 2005-05-10 | Fujisawa Pharmaceutical Co., Ltd. | Brain-protective agent |
| AU753270B2 (en) * | 1998-05-21 | 2002-10-10 | Isis Pharmaceuticals, Inc. | Compositions and methods for topical delivery of oligonucleotides |
| EP1080103A4 (en) * | 1998-05-21 | 2003-07-02 | Isis Pharmaceuticals Inc | PREPARATIONS AND METHOD FOR THE NON-PARENTERAL ADMINISTRATION OF OLIGONUCLEOTIDES |
| US20030206958A1 (en) * | 2000-12-22 | 2003-11-06 | Cattaneo Maurizio V. | Chitosan biopolymer for the topical delivery of active agents |
| US6187587B1 (en) * | 2000-03-02 | 2001-02-13 | Isis Pharmaceuticals, Inc. | Antisense inhibition of e2f transcription factor 1 expression |
| US20050125054A1 (en) * | 2000-12-22 | 2005-06-09 | Avantec Vascular Corporation | Devices delivering therapeutic agents and methods regarding the same |
| US20050203612A1 (en) * | 2000-12-22 | 2005-09-15 | Avantec Vascular Corporation | Devices delivering therapeutic agents and methods regarding the same |
| JP4346233B2 (ja) * | 2000-12-27 | 2009-10-21 | アンジェスＭｇ株式会社 | デコイを含む薬学的組成物およびその使用方法 |
| EP1690544B1 (en) * | 2001-02-20 | 2017-09-13 | AnGes MG, Inc. | Pharmaceutical composition containing decoy and method of using the same |
| AU2002349402B2 (en) * | 2001-11-22 | 2008-01-31 | Anges Mg, Inc. | Compositions inhibiting rejection in organ transplantation and method of using the same |
| WO2003063911A1 (en) * | 2002-02-01 | 2003-08-07 | Anges Mg, Inc. | Decoy-containing pharmaceutical compositions and method of using the same |
| US20060135449A1 (en) * | 2002-03-29 | 2006-06-22 | Yoshiki Sawa | Decoy compositions for treating and preventing brain diseases and disorders |
| PT2264172T (pt) * | 2002-04-05 | 2017-12-06 | Roche Innovation Ct Copenhagen As | Compostos oligoméricos para a modulação da expressão do hif-1α. |
| US20060241066A1 (en) * | 2002-05-29 | 2006-10-26 | Tetsuya Tomita | Decoy composition for treating and preventing inflammatory disease |
| AU2003303521A1 (en) * | 2002-12-31 | 2004-07-29 | Genta Incorporated | Combination of gallium compounds with nonchemotherapeutic anticancer agents in the treatment of neoplasia |
| US20040191779A1 (en) * | 2003-03-28 | 2004-09-30 | Jie Zhang | Statistical analysis of regulatory factor binding sites of differentially expressed genes |
| EP1462111A1 (en) * | 2003-03-28 | 2004-09-29 | Universiteit Utrecht Holding B.V. | Composition for inducing immunotolerance |
| EP1691817A2 (en) * | 2003-12-02 | 2006-08-23 | Corgentech, Inc. | NF-kB OLIGONUCLEOTIDE DECOY MOLECULES |
| WO2005056795A2 (en) * | 2003-12-03 | 2005-06-23 | Corgentech, Inc. | Hif oligonucleotide decoy molecules |
| US7585848B2 (en) * | 2005-01-11 | 2009-09-08 | Rush University Medical Center | Methods and compositions for treating, inhibiting and reversing disorders of the intervertebral disc |
| US20060258604A1 (en) * | 2005-05-10 | 2006-11-16 | Warren Strober | Compositions and methods for the treatment of inflammatory bowel disease utilizing NF-kappaB decoy polynucleotides |
-
2005
- 2005-09-21 EP EP05800264A patent/EP1799271A4/en not_active Withdrawn
- 2005-09-21 MX MX2007003167A patent/MX2007003167A/es not_active Application Discontinuation
- 2005-09-21 WO PCT/US2005/034110 patent/WO2006034433A2/en not_active Ceased
- 2005-09-21 AU AU2005286640A patent/AU2005286640A1/en not_active Abandoned
- 2005-09-21 JP JP2007532679A patent/JP2008513513A/ja active Pending
- 2005-09-21 US US11/233,511 patent/US20060069055A1/en not_active Abandoned
- 2005-09-21 CA CA002583413A patent/CA2583413A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008513513A5 (enExample) | ||
| KR102623786B1 (ko) | 근위축증 및 근긴장성 이영양증을 치료하는 조성물 및 방법 | |
| AU2014259755B2 (en) | Compositions and methods for modulating apolipoprotein (a) expression | |
| CN108136206B (zh) | 抗乙型肝炎病毒的组合物和药剂及其用途 | |
| JP2018536689A5 (enExample) | ||
| JP2018184423A5 (enExample) | ||
| JP2010528041A5 (enExample) | ||
| JP2019518037A (ja) | Ｂ型肝炎感染症治療用のＰＡＰＤ５又はＰＡＰＤ７のｍＲＮＡ減少用核酸分子 | |
| JP2013510561A5 (enExample) | ||
| JP2016502858A5 (enExample) | ||
| JP2005512976A5 (enExample) | ||
| CN102459587A (zh) | 结合海帕西啶的核酸 | |
| JP2007504830A5 (enExample) | ||
| JP2009528346A5 (enExample) | ||
| JP2016513976A5 (enExample) | ||
| TWI740866B (zh) | 肽寡核苷酸結合物 | |
| ES3001019T3 (es) | Inhibidores del MICRO-RNA 22 | |
| JP2006502243A5 (enExample) | ||
| JP2013526519A (ja) | アンチセンスオリゴヌクレオチドを含む医薬組成物およびそれを使用する方法 | |
| Mukai et al. | Renal press-mediated transfection method for plasmid DNA and siRNA to the kidney | |
| JP2019523302A5 (enExample) | ||
| US9492470B2 (en) | Use of HMGA-targeted phosphorothioate DNA aptamers to suppress carcinogenic activity and increase sensitivity to chemotherapy agents in human cancer cells | |
| JP6049143B2 (ja) | オリゴヌクレオチド、グルココルチコイド感受性増強剤、医薬組成物、及び発現ベクター | |
| WO2017043639A1 (ja) | キメラデコイ | |
| JP6830441B2 (ja) | 治療上のｕｎａオリゴマーおよびその使用 |